Follow the 제넨바이오 share price and the full directors' dealings record of the company, a listed issuer based in South Korea. Shares are quoted on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 제넨바이오 has logged 38 reports. The latest transaction was reported on 14 March 2024 (Other). Among the most active insiders: 메리츠증권. The full history is openly available.
38
Insider Decl.
n/a
Thresholds
n/a
8 ops.
Buy Volume
n/a
7 ops.
Sell Volume
5Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Genenbio is in the healthcare and pharmaceutical sector, listed on the XKRX market. The company focuses on developing innovative biopharmaceutical solutions.